Relay Therapeutics share price logo

Relay Therapeutics

NASDAQ: RLAY

Mid Cap

$18.97

-0.09

(-0.47%)

as on

Relay Therapeutics Stock Performance

as on September 16, 2026 at 2:15 pm IST

  • Day's Low

    Day's High

    $18.64
    $19.07
    downward going graph

    1.74%

    Downside

    0.53%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $3.89
    $21.27
    downward going graph

    79.52%

    Downside

    12.12%

    Upside

    downward going graph

Relay Therapeutics share price movements today

Previous Close
$19.06
Open
$18.78
Volume
2.1M
Market Cap
$4.1B
Day's Low - High
$18.64 - $19.07
52 Week Low - High
$3.89 - $21.27

Relay Therapeutics Historical Returns

1 Month Return
-4.03 %
3 Month Return
+ 27.41 %
1 Year Return
+ 369.46 %
3 Year Return
+ 103.42 %
5 Year Return
-48.39 %

Relay Therapeutics Stock Fundamentals & Key Indicators

Check Relay Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$4.1B

EPS (TTM)

-1.6158

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-308.2M

Revenue (TTM)

10.3M

Profit Margin

0.00%

Return On Equity TTM

-36.77%

Relay Therapeutics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Relay Therapeutics with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Relay Therapeutics image
Relay Therapeutics
BUY$4.1B-48.39%NA0.00%NA
Revolution Medicines image
Revolution Medicines
BUY$44.6B614.61%NA0.00%NA
Vertex Pharmaceuticals image
Vertex Pharmaceuticals
BUY$130.6B175.08%29.7686.04%NA
Moderna image
Moderna
BUY$57.5B-66.24%-18.04-12.57%NA
Regeneron image
Regeneron
BUY$80.5B21.74%18.9584.86%47.339999999999996%

Stock Returns calculator for Relay Therapeutics Stock including INR - Dollar returns

The Relay Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

Relay Therapeutics investment value today

Current value as on today

₹5,08,774

Returns

₹4,08,774

(+408.77%)

Returns from Relay Therapeutics Stock

₹3,67,241 (+367.24%)

Dollar Impact

₹41,532 (+41.53%)

Analyst Recommendation on Relay Therapeutics Stock

Based on 9 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 9 analysts, 100% of analysts recommend a 'BUY' rating for Relay Therapeutics. Average target price of $27.08

Relay Therapeutics Share Price Target

Get share price movements and forecasts by analysts on Relay Therapeutics.

What analysts predicted

29.95%UPSIDE

Target Price

$27.08

Current Price

$18.97

Analyzed by

9 Analysts

Target

$27.08

Relay Therapeutics target price $27.08, a slight upside of 29.95% compared to current price of $18.97. According to 9 analysts rating.

Indian Investors' Interest in Relay Therapeutics Stock

Search interest for Relay Therapeutics Stock has increased by 24% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:24% versus previous 30 day period

Relay Therapeutics Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
10
-
-
-
7
0
-
7
3
0
Gross Profit
-72
-91
-76
-64
7
-60
-67
6
2
0
Operating Income
-90
-100
-96
-84
-84
-76
-80
-60
-78
-90
EBITDA
-90
-110
-86
-74
-75
-69
-73
-57
-72
-82
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
1
1
1
1
1
1
0
0
0
0
Income Before Tax
-81
-92
-88
-76
-77
-70
-74
-54
-73
-83
Income Tax Expense
1
-
-
-
-
-
-
-
-
-
Net Income
-81
-92
-88
-76
-77
-70
-74
-54
-73
-83
Net Profit Margin
-813.30%
0.00%
0.00%
0.00%
-1003.58%
-10395.13%
0.00%
-784.14%
-2443.03%
-23916.29%

Relay Therapeutics Annual Profit & Loss

All numbers in Millions USD

Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
-
-
82
3
1
25
10
15
Gross Profit
-2
-2
79
-166
-241
-300
-305
11
Operating Income
-49
-84
-55
-364
-299
-373
-372
-302
EBITDA
-47
-81
-52
-223
-306
-374
-380
-272
Interest Expense
-
-
-
0
8
-
-
-
Depreciation
2
2
3
3
4
5
5
3
Income Before Tax
-48
-75
-52
-363
-290
-341
-337
-276
Income Tax Expense
1
-8
-3
132
-36
-37
-337
-
Net Income
-48
-66
-52
-363
-290
-341
-337
-276
Net Profit Margin
0.00%
0.00%
-63.41%
-12012.94%
-21036.13%
-1338.66%
-3374.72%
-1800.58%

Relay Therapeutics Quarterly Cash Flow

All numbers in Millions USD

Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-92
-88
-76
-77
-70
-74
-54
-73
-83
Operating Cash Flow
-65
-75
-57
-73
-55
-62
-44
-51
-54
Investing Cash Flow
45
-126
28
42
75
39
35
32
-353
Financing Cash Flow
1
218
0
-
0
0
0
138
323
Change in Cash
-18
17
-28
-30
20
-22
-8
120
-83

Relay Therapeutics Annual Cash Flow

All numbers in Millions USD

Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-75
-52
-363
-290
-341
-337
-276
Operating Cash Flow
-66
-102
-74
-229
-300
-249
-235
Investing Cash Flow
-319
81
-479
-188
257
-41
192
Financing Cash Flow
5
426
388
289
34
270
1
Change in Cash
-379
405
-165
-128
-7
-20
-41

Mutual Funds that own Relay Therapeutics Stock

Check out the Mutual Funds with significant holdings in Relay Therapeutics.

Funds
Holdings
Shares Held
VANGUARD INDEX FUNDS
3.28658%
7202265
Fidelity Concord Street Trust
0.818286%
1793207
Fidelity Salem Street Trust
0.724361%
1587378
Fidelity Advisor Series VII
0.697676%
1528900
DFA INVESTMENT DIMENSIONS GROUP INC
0.660916%
1448344
See all

Global Institutional Holdings in Relay Therapeutics

Funds
Holdings
Joseph Edelman
6.44%
Vanguard
4.76%
iShares
3.78%
SPDR
3.25%
Felix Baker
1.29%
See all

Relay Therapeutics News & Key Events

  • img

    Today's Timeline - 03 December

    Wed, 07:17 PM

    -

    Commodore Capital increased its stake in Relay Therapeutics by 3.65 million shares, raising its position to 17 million shares.

    Wed, 07:26 PM

    -

    Relay Therapeutics' Director sold $300,000 worth of shares, primarily due to company policy on stock compensation.

Insights on Relay Therapeutics

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 3 months, RLAY stock has moved up by 26.0%

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, RLAY has outperformed top 5 stocks with highest market-cap in its industry

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 478.8% return, outperforming this stock by 119.5%

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 3 quarters, 7.0M → 350.0K (in $), with an average decrease of 72.7% per quarter

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 3 quarters, -54.89M → -83.70M (in $), with an average decrease of 23.9% per quarter

About Relay Therapeutics

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and aGal chaperone for Fabry diseases. It also develops RLY-8161, an oncogene driver that belongs to the RAS family of signaling proteins. In addition, the company develops lirafugratinib (RLY-4008), a receptor tyrosine kinase for the treatment of cancer. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; Elevar Therapeutics, Inc. for the development and commercialization of RLY-4008; and Pfizer Inc. for the development of RLY-2608 in combination with fulvestrant and atirmociclib. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
OrganisationRelay Therapeutics
Headquarters60 Hampshire Street, Cambridge, MA, United States, 02139
IndustryBiotechnology
CEODr. Sanjiv K. Patel M.A., M.B.A., M.D., MBBS
E-voting on sharesClick here to vote

Key Management of Relay Therapeutics

Name

Title

Dr. Donald A. Bergstrom M.D., Ph.D.

President of Research & Development

Dr. Matthew P. Jacobson Ph.D.

Founder

Mr. Jim Watters Ph.D.

Chief Scientific Officer

Ms. Soo-Yeun Lim J.D.

Senior VP & General Counsel

Mr. Thomas Catinazzo

Chief Financial Officer

Mr. Peter Rahmer

Chief Corporate Development Officer

Ms. Dorothee Kern Ph.D.

Founder

Dr. David Elliot Shaw Ph.D.

Founder

Dr. Sanjiv K. Patel M.A., M.B.A., M.D., MBBS

CEO, President & Director

Dr. Mark Murcko Ph.D.

Founder & Independent Director

FAQs

What is Relay Therapeutics share price today?

Relay Therapeutics share price today is $18.97 as on at the close of the market. Relay Therapeutics share today touched a day high of $19.07 and a low of $18.64.

What is the 52 week high and 52 week low for Relay Therapeutics share?

Relay Therapeutics share touched a 52 week high of $21.27 on and a 52 week low of $3.89 on . Relay Therapeutics stock price today i.e. is closed at $18.97,which is 10.81% down from its 52 week high and 388.29% up from its 52 week low.

What is Relay Therapeutics's market capitalisation today?

Relay Therapeutics market capitalisation is $0.00T as on .

How to invest in Relay Therapeutics Stock (RLAY) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Relay Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Relay Therapeutics Shares that will get you 0.0791 shares as per Relay Therapeutics share price of $18.97 per share as on September 16, 2026 at 8:45 am IST.

What is the minimum amount required to buy Relay Therapeutics Stock (RLAY) from India?

Indian investors can start investing in Relay Therapeutics (RLAY) shares with as little as ₹95.955 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹959.55 in Relay Therapeutics stock (as per the Rupee-Dollar exchange rate as on ). Based on Relay Therapeutics share’s latest price of $18.97 as on September 16, 2026 at 8:45 am IST, you will get 0.5271 shares of Relay Therapeutics. Learn more about fractional shares .

What are the returns that Relay Therapeutics has given to Indian investors in the last 5 years?

Relay Therapeutics stock has given -48.39% share price returns and 30.13% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?